Recombinant Anti-CD32B x Anti-CD79B Bispecific Antibody (Single-chain Diabody) (SCDB-112)

Recombinant Anti-CD32B x Anti-CD79B Bispecific Antibody (Single-chain Diabody) is designed to be expressed as one polypeptide chain with four variable domains from two parental antibodies. The middle linker is long enough to form scFv dimers between the two diabody chains. This BsAb can regulate B-cell modulation. It is designed for the research of Immune diseases therapy.

Datasheet INQUIRY

Specifications

Targets

CD32B & CD79B

Type

Single-chain Diabody

Species Reactivity

Human

Application

FuncS; Promising therapeutic agent

Related Disease

Immune diseases

Targets

Target 1

CD32B

Gene ID

2213

UniProt ID

P31994

Alternative Names

FCGR2B; Fc fragment of IgG, low affinity IIb, receptor (CD32); FcγRIIB; CD32; FCG2; CD32B; FCGR2; IGFR2; low affinity immunoglobulin gamma Fc region receptor II-b; CDw32; fcRII-b; Fc gamma RIIb; fc-gamma-RIIb; fc-gamma RII-b; igG Fc receptor II-b; Fc fragment of IgG, low affinity II, receptor for (CD32); Fc fragment of IgG, low affinity IIb, receptor for (CD32)

Target 2

CD79B

Gene ID

974

UniProt ID

P40259

Alternative Names

CD79B; CD79b molecule, immunoglobulin-associated beta; Cluster of differentiation 79B; CD79b antigen; B29; IGB; AGM6; B-cell antigen receptor complex-associated protein beta chain; Ig-beta; B-cell-specific glycoprotein B29; immunoglobulin-associated B29 protein; CD79b antigen (immunoglobulin-associated beta); immunoglobulin-associated CD79 beta

Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.

Online Inquiry

Customer Reviews and Q&As

There are currently no customer reviews or questions for Recombinant Anti-CD32B x Anti-CD79B Bispecific Antibody (Single-chain Diabody) (SCDB-112). Click the button below to contact us or submit your feedback about this product.

Recombinant Anti-CD32B x Anti-CD79B Bispecific Antibody (Single-chain Diabody) (CAT#: SCDB-112)

Specifications

Targets

Customer Reviews and Q&As